Eli Lilly CEO David Ricks on positive Alzheimer's drug trial data

0
80

Eli Lilly said on Monday a trial of its experimental Alzheimer’s drug donanemab showed it slowed by about a third the rate of decline in a combined measure of …

source

LEAVE A REPLY

Please enter your comment!
Please enter your name here